Gastro One (Walnut Run Road)

The trials here

What the 2 trials at this site are about, from their registry records.

Conditions

• Fatty liver disease (MASLD/MASH)1 trial
• Ulcerative colitis1 trial

Phase

• Phase 21 trial
• Phase 31 trial

Status

• Recruiting2 trials

Lead sponsor

• Eli Lilly and Company2 trials

Running trials

• Recruiting

  LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  NCT07186101· Phase 2· Eli Lilly and Company· Source

  Contact: Ziad Younes (principal investigator)

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Ziad Younes (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Ulcerative colitis1 recruiting